C6O — Clovis Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- €2.17m
- €538.48m
- $148.76m
Annual cashflow statement for Clovis Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -346 | -368 | -400 | -369 | -265 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 152 | 52.6 | 60.7 | 96.3 | 29.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -65.6 | -55.2 | 8.33 | 12 | 30.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -261 | -366 | -324 | -253 | -196 |
| Capital Expenditures | -4.1 | -64.2 | -19 | -8.35 | -0.312 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -50 | -200 | 162 | 135 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -54.1 | -264 | 143 | 126 | -0.312 |
| Financing Cash Flow Items | — | -0.035 | -0.16 | -0.211 | -0.213 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 562 | 388 | 120 | 204 | 100 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 248 | -242 | -60 | 78.4 | -96.8 |